Condition
Overweight
Obesity
Locations
Greece, Hungary, Portugal, Serbia, Sweden, United States
Start date
04/08/2026
Identifiers
Trial ID NN9833-8550,
NCT number NCT07745504,
Eudract number Not Available
NCT number NCT07745504,
Eudract number Not Available
Summary
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.
Trial Overview:
Treatment
DRUG: Cagrilintide
DRUG: Placebo cagrilintide
DRUG: Placebo semaglutide
Study type
INTERVENTIONAL
Trial duration
Aug 04 2026 - Jul 06 2027
Participants
285
Phase
III
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.